Retrospective study of the predictors of mortality and radiographic deterioration in 782 patients with nodular/bronchiectatic Mycobacterium avium complex lung disease

BMJ Open. 2015 Aug 5;5(8):e008058. doi: 10.1136/bmjopen-2015-008058.

Abstract

Objectives: Some patients with nodular/bronchiectatic Mycobacterium avium complex lung disease (NB MAC-LD) deteriorate and die. The main aim of the study is to evaluate the prognostic factors and radiographic outcomes in patients with NB MAC-LD.

Setting: Retrospective single-centre review.

Participants: 782 HIV-negative patients with NB MAC-LD treated at our institution in Japan.

Primary and secondary outcome measures: All-cause and MAC-LD progression mortality rates and the prognostic factors, and radiographic deterioration rates and the prognostic factors.

Results: Mean age was 68.1 years, and median follow-up period was 4.3 years. Death from any cause and progression of MAC lung disease (MAC-LD) occurred in 130 (16.6%), and 19 (2.4%) patients, respectively. All-cause and MAC-LD progression 10-year mortality rates were 27.4% and 4.8%, respectively. In 536 patients with MAC-LD who were followed-up for more than 1 year, radiographic deterioration occurred in 221 (41.2%) patients and median time-to-radiographic deterioration was 9 years. A multivariate Cox proportional hazard model showed male sex, older age, body mass index <18.5 kg/m(2), absence of bloody sputum, hypoalbuminaemia and erythrocyte sedimentation rate >40 mm/h to be negative prognostic factors for all-cause mortality, and the presence of idiopathic pulmonary fibrosis, haemoglobin <11.3 mg/dL, C reactive protein >1.0 mg/dL and the presence of cavity to be negative prognostic factors for radiographic deterioration.

Conclusions: Only 2.4% of patients with NB MAC-LD died from MAC-LD progression. As clinical trials testing the effectiveness of drug therapy in patients with NB MAC-LD are being designed and implemented, the primary end point could be time-to-radiographic deterioration, and trial patients need to be stratified according to these prognostic factors before randomisation.

MeSH terms

  • Aged
  • Anti-Bacterial Agents / classification
  • Anti-Bacterial Agents / therapeutic use*
  • Bronchiectasis / complications*
  • Bronchiectasis / microbiology
  • Cause of Death
  • Disease Progression
  • Female
  • HIV Seronegativity
  • Humans
  • Japan / epidemiology
  • Kaplan-Meier Estimate
  • Lung / microbiology*
  • Lung Diseases / microbiology
  • Lung Diseases / mortality*
  • Male
  • Middle Aged
  • Multivariate Analysis
  • Mycobacterium avium Complex / genetics
  • Mycobacterium avium-intracellulare Infection / mortality*
  • Prognosis
  • Proportional Hazards Models
  • Retrospective Studies
  • Risk Factors
  • Sputum / microbiology

Substances

  • Anti-Bacterial Agents